In this regard, in line with recent reports on BRAF-mutated melanoma [10, 31], we found that diclofenac, a non-steroidal anti-inflammatory drug (NSAID), is able to impair the glycolytic flux of tumour cells and—synergistically with B-raf inhibitors (i.e., either vemurafenib or dabrafenib)—to reduce the viability of papillary and anaplastic thyroid cancer cells. Here, BRAF is linked to melanoma.